Radiolabeling fingolimod with technetium-99 m and evaluating its biological affinity by in vitro method
No Thumbnail Available
Date
2023
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Fingolimod (FTY-720) is the first oral medication approved by the food and drug administration (FDA) for the treatment of multiple sclerosis. It acts on the central nervous system by crossing the blood–brain barrier and binding to sphingosine-1-phosphate receptors (S1PRs). FTY-720 protects against neural damage caused by mitochondrial dysfunction and cytotoxicity by modulating S1PR1. In this study, FTY-720 was radiolabeled with technetium-99 m [99mTc]Tc and the biological affinity of [99mTc]Tc-FTY-720 was assessed using in vitro methods. The radiochemical yield and stability of [99mTc]Tc-FTY-720 was over 95% during 4 h. [99mTc]Tc-FTY-720 showed uptake on the SH-SY5Y cell line. © 2023, Akadémiai Kiadó, Budapest, Hungary.
Description
Keywords
fingolimod , FTY 720 tc 99m , radiopharmaceutical agent , sphingosine 1 phosphate receptor , unclassified drug , Article , binding affinity , controlled study , drug binding , drug stability , drug uptake , human , human cell , in vitro study , lipophilicity , multiple sclerosis , Parkinson disease , radioactivity , radiochemistry , radiolabeling , SH-SY5Y cell line